Pfizer’s PARP inhibitor, Talzenna, is set to face significant challenges as the FDA has rejected its application for wider use in treating patients with non-High Risk Repeat (HRR) mutations. The decision will have implications for pharmaceutical companies seeking to expand treatment indications.
Analysts expect a potential upside of 16.43% for Pfizer shares, with a target price of $28.57, according to recent estimates. GuruFocus also suggests an 11.17% upside based on its GF Value metric.
Despite the setback, Wall Street analysts have set a one-year price target at $28.57, indicating a potential increase from the current market price of $24.54. Brokerage recommendations for Pfizer are generally positive, with 25 firms placing the company at a “Hold” status and an average recommendation score of 2.6.
Pfizer’s valuation is estimated to be around $27.28 by GuruFocus, implying an upside of 11.17% from the current price. The FDA decision highlights the regulatory challenges pharmaceutical companies face when seeking to broaden treatment indications.
Source: https://www.gurufocus.com/news/2927373/fda-denies-pfizers-pfe-label-expansion-for-talzenna-in-prostate-cancer?mobile=true